Aplastic anemia (AA) is a rare disease with a major autoimmune pathogenetic component. CTLA4 is a Tlymphocyte surface molecule involved in the maintenance of immune tolerance. Some polymorphisms associated with a reduced expression of CTLA4, and thus presumably with increased tendency to autoimmunity, have been associated with various autoimmune diseases. In this study, we evaluated the distribution of the low expression polymorphisms À318C4T and 49A4G of CTLA4 in a population of 67 patients with acquired AA and in 100 normal controls. There was no difference in the distribution of the tested polymorphism between patients and controls and, within the patient group, between those who responded to immunosuppression vs those who did not respond. This study indicates that the polymorphisms À318C4T and 49A4G of CTLA4 do not affect the risk of developing AA and do not influence the response to immunosuppression. Bone Marrow Transplantation (2005) 35, S89-S92.
Summary:
Aplastic anemia (AA) is a rare disease with a major autoimmune pathogenetic component. CTLA4 is a Tlymphocyte surface molecule involved in the maintenance of immune tolerance. Some polymorphisms associated with a reduced expression of CTLA4, and thus presumably with increased tendency to autoimmunity, have been associated with various autoimmune diseases. In this study, we evaluated the distribution of the low expression polymorphisms À318C4T and 49A4G of CTLA4 in a population of 67 patients with acquired AA and in 100 normal controls. There was no difference in the distribution of the tested polymorphism between patients and controls and, within the patient group, between those who responded to immunosuppression vs those who did not respond. This study indicates that the polymorphisms À318C4T and 49A4G of CTLA4 do not affect the risk of developing AA and do not influence the response to immunosuppression. Bone Marrow Transplantation (2005) 35, S89-S92. doi:10.1038/sj.bmt.1704855 Keywords: aplastic anemia; CTLA4 polymorphisms; immunosuppressive therapy Aplastic anemia (AA) is a rare disease in which the low level of the circulating blood cells derives from the reduction of marrow hematopoietic stem cells. This, according to the currently most accredited pathogenic model, derives from the activation of autoreactive T cells that liberate myelosuppressive cytokines like IFN-g and TNF-a that damage the marrow hematopoietic stem cells. Although the marrow stem cell antigen against which the T-cell attack is directed is not known at the moment, there is much evidence for a relevant autoimmune T-cellmediated component in the pathogenesis of AA [1] [2] [3] including the high rate of response to immunosuppressive therapy (IS) displayed by AA patients. 4 CTLA4 is a surface molecule expressed on activated T cells that downregulates T-cell autoreactivity, thus leading to self-tolerance. Some polymorphisms of CTLA4 are associated with different levels of expression of this molecule on cell surface. Those which are linked to reduced protein expression, such as À318C4T in the promoter and 49A4G in exon 1 of CTLA4, 5, 6 have been associated with increased frequency of autoimmune diseases like Graves' disease, autoimmune hypothyroidism, type 1 diabetes and multiple sclerosis. [7] [8] [9] In the current study, we aimed to evaluate whether the low expression CTLA4 polymorphisms À318C4T and 49A4G were associated with the risk of developing AA and whether they were linked to a worse response to IS therapy.
Materials and methods
In all, 67 nonconsecutive Caucasian AA patients were included in the study. After informed consent was obtained from the patients' parents or the patients themselves, stored samples of either peripheral blood or bone marrow was used for DNA analysis. Normal controls were 100 cord blood samples from healthy Italian neonates who reflected the ethnicity and gender distribution of the patient population. Informed consent was obtained from the parents.
DNA extraction
Genomic DNA was extracted from whole peripheral blood leukocytes.
Polymerase chain reaction (PCR)
The polymorphisms À318C4T in the promoter and 49A4G in exon 1 of CTLA4 were amplified using four primers: 5 0 -AAGGATGCCCAGAAGATTGA-3 0 and 5 0 -AGCCGTGGGTTTAGCTGTTA-3 0 ; 5 0 -CTGAACACCG CTCCCATAAA-3 0 and 5 0 -TTGCAGAAGACAGGGAT GAA-3 0 , respectively. The PCR mixture contained 100 ng of genomic DNA, 0.1 mM each of the deoxynucleotide triphosphates, 12.5 pmol each of the primers and 1 U of Taq polymerase (Applied Biosystem, Foster city, CA, USA) in a 25 ml final volume. The samples were heated at 941C for 2 min, followed by 35 cycles of 941C for 30 s, 581C for 30 s and 721C for 30 s, with a final extension at 721C for 7 min.
Restriction fragment length polymorphism (RFLP)
The RFLP assay was performed in a 15 ml reaction volume containing PCR product and specific restriction enzymes (MseI for the polymorphism À318C4T in the promoter and BbvI for the polymorphism 49A4G in exon 1). The digestion products were visualized on a 3% agarose gel stained with ethidium bromide. In the presence of the CTLA4 À318T allele, MseI cut the 212-bp PCR product into two bands of 118 and 94 bp, respectively. Instead, in the presence of the CTLA4 49G allele, BbvI cut the 130 bp PCR product into two bands of 74 and 56 bp, respectively. CTLA4 typing by the amplification-created restriction site method was successfully confirmed by automated DNA sequencing.
Descriptive statistics were reported as absolute frequencies and percentages for qualitative data. Comparison of genotypes and of allelic frequencies between patients and controls, and between responders and nonresponders to IS was performed by means of the w 2 test or the Fisher's exact test in case of expected frequencies less than 5. All the statistical tests were two sided; a P-value o0.05 was considered as statistically significant. The statistical package 'Stata' (STATA, release 7, Stata Corporation, College Station, TX, USA) was used to perform all the analyses. Table 1 shows the characteristics of the 67 AA patients and of the 100 normal controls. Table 2A and B report the distribution of the polymorphism À318C4T and 49A4G of CTLA4, whose agarose gel electrophoresis is shown in Figure 1 .
Results
The distribution of the of the tested polymorphism of CTLA4, both if expressed as genotype and as allelic frequency, was very similar in AA patients and in normal controls. The distribution of the CTLA4 polymorphisms found in our controls overlapped that seen by others 5, 8, 10, 11 in Caucasian subjects. Also, the distribution of both the genotypes and allele frequencies of À318C4T and 49A4G did not differ between the group of AA patients who responded to IS therapy vs those who did not (Table 3A and B). e Patients may be counted more than once, that is, five patients who did not respond to 2 or more cycles of IS therapy then underwent BMT, and three patients did other IS therapy (steroid) before undergoing BMT.
Table 2
Distribution of the polymorphism (A) 49A4G in exon 1 and (B) -318C4T in the promoter region of CTLA4 in AA patients and in normal controls, expressed as genotype and as allele frequency 
Discussion
To the best of our knowledge, this study is the largest ever conducted on the relationship between AA subjects and CTLA4 polymorphisms in Caucasian populations. It indicates that there is no association between AA and the low expression CTLA4 polymorphisms that can theoretically be considered 'pro autoimmunity/pro AA' genotypes. This suggests that CTLA4 polymorphisms do not impact on the risk of developing AA. Nevertheless, our data are not conclusive regarding the pathogenic role of CTLA4. In fact, CTLA4 expression on T-lymphocytes of AA patients was not assessed in this study and thus we cannot confirm that the 'pro autoimmunity' CTLA4 genotypes do correspond to decreased expression of this molecule on T-cell surface of AA patients. In addition, it has to be noted that polymorphisms associated with CTLA4 expression are unlikely to be the only regulators of the complex mechanism of break down of self-tolerance, which may lead to an autoimmune condition like AA. It is possible that other molecules, such as inhibitory Fc gamma receptors class IIb (Fcgamma RIIb) 12, 13 or C/EBPbeta that might influence FasL activity, 14 have a role in the pathogenesis of AA. The lack of association between the tested CTLA4 polymorphisms and response to IS therapy indicates that these polymorphisms do not affect the response of AA to this treatment. It is highly probable that other factors, such as the number of residual stem cell, the number of autoreactive T cells circulating at a time or the cytokine burden, play a more important role in this respect. Similar to the pathogenic issue not having evaluated the CTLA4 expression on T cells in AA responders and nonresponders to IS therapy impedes drawing a conclusion regarding the true role of CTLA4 expression in response to IS therapy.
Conclusion
In summary, this study indicates that low expression polymorphisms of CTLA4 neither affect the risk of developing AA nor impact on the response to IS. Assessment of expression of CTLA4 on marrow lymphocytes of AA patients may help to clarify the role of this modulator in the pathogenesis of this disease. 
